Loading clinical trials...
Loading clinical trials...
A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Assess the Efficacy and Safety of Clazosentan in Preventing Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI), in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH)
Conditions
Interventions
Clazosentan
Placebo
Locations
80
United States
Stanford Hospital & Clinics - Stanford School of Medicine Dept. of Neurosurgery
Stanford, California, United States
Mayo clinic, Dept of Neurosurgery
Jacksonville, Florida, United States
University of Illinois - Department of Neurosurgery
Chicago, Illinois, United States
University of Maryland Medical Systems - Neurosurgery
Baltimore, Maryland, United States
Boston University School of Medicine / Boston University Medical Center
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center Dept of Neurosurgery
Boston, Massachusetts, United States
Start Date
February 3, 2019
Primary Completion Date
June 13, 2022
Completion Date
November 18, 2022
Last Updated
January 10, 2024
NCT07160088
NCT07307508
NCT06409364
NCT04566991
NCT04507178
NCT04490161
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions